4.9Industry

Pharmacy & Life Sciences

CROs, CDMOs, specialty pharmaceutical manufacturers, diagnostic labs, and pharmacy benefit managers supporting the drug development and distribution continuum.

8
Segments
32
Verticals

Overview

Pharmacy & Life Sciences spans the drug value chain: biopharmaceutical manufacturing, retail and specialty pharmacy, pharmacy benefit management, clinical research and contract manufacturing, laboratory and diagnostic services, and life-sciences services. It is one of the largest and most strategically important parts of healthcare.

Biopharma M&A is driven by patent cliffs and the GLP-1 boom; the PBM oligopoly is under intense regulatory and political scrutiny over drug pricing; retail pharmacy is consolidated and financially stressed; and CRO/CDMO outsourcing is booming with drug-development demand. Note that revenue overlaps across the chain. The same drug is counted at manufacturing, PBM, and retail stages, so segment figures are not additive.

Market snapshot

FragmentationConsolidatingEstimate

The drug value chain double-counts itself. The same prescription is booked at manufacturing (biopharma ~$211B), again at the PBM (~$284B), and again at the pharmacy counter (~$544B), so these segments are never summed into a sector total. Each behaves differently: branded biopharma is high-margin and patent-cliff-driven, PBMs are a tight regulated oligopoly earning a thin management spread, retail pharmacy is consolidated and margin-stressed, and CRO/CDMO outsourcing plus lab services are the fast-growing services layer.

Business model & economics

Revenue model

Drug sales, dispensing margin, benefit management, and services

Key economics

Recurring revenue
High

recurring prescriptions and services

EBITDA margin
Varies widely

high for branded pharma, thin for pharmacy

Capex intensity
High

Characteristics

  • Patent cliffs and GLP-1 drive biopharma M&A.
  • PBM oligopoly under intense regulatory scrutiny.
  • CRO/CDMO outsourcing booming with drug-development demand.

Geographic concentration

AlabamaAlaskaArizonaColoradoFloridaGeorgiaIndianaKansasMaineMinnesotaNorth CarolinaNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasDelawareDistrict of ColumbiaHawaiiIowaKentuckyMichiganMississippiMontanaNew HampshireNew YorkOhioOregonTennesseeUtahVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoNevadaVermontLouisianaRhode IslandMassachusettsNew JerseyCaliforniaMaryland

Pharmacy and life sciences concentrate in the established biopharma corridors: Massachusetts, California, New Jersey, and Maryland.

MassachusettsCaliforniaNew JerseyMaryland

U.S. Census Bureau, 2022 Statistics of U.S. Businesses (firms by state), aggregated across this section's biopharma, CRO, and CDMO lines. Concentration shown by location quotient.

M&A deal context

Deal activityHigh

Who’s acquiring

  • Big pharma & biopharma strategics
  • CRO/CDMO consolidators
  • Pharmacy, PBM & payer integrators

What’s driving deals

  • Patent-cliff-driven biopharma acquisition.
  • CRO/CDMO outsourcing consolidation.
  • PBM and pharmacy vertical integration and scrutiny.

Segments in this industry

Find Pharmacy & Life Sciences acquisition targets

Search Acquisera’s index for companies classified under Pharmacy & Life Sciences (4.9) and build a targeted deal pipeline.

Search companies